SEC Form 4 · accession 0001562180-17-003381
BIO-TECHNE Corp · TECH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert M. Gavin
Officer — Sen. VP Protein Platforms
Period of report
Oct 26, 2017
Accepted (ET)
Oct 30, 2017 · 4:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000842023
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 1,667 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Oct 26, 2017 | A | 1,949 | A | — | — | Common Stock | 1,949 | 1,949 | D |
| Stock Options (Right to buy)F2 | $125.05 | Oct 26, 2017 | A | 10,742 | A | — | Aug 9, 2024 | Common Stock | 10,742 | 10,742 | D |
| Stock Options (Right to buy)F3 | $125.05 | Oct 26, 2017 | A | 14,323 | A | — | Aug 9, 2024 | Common Stock | 14,323 | 14,323 | D |
| Restricted Stock UnitsF4,F5 | — | holding | — | — | — | — | — | Common Stock | 1,500 | 1,500 | D |
| Restricted Stock UnitsF1,F6 | — | holding | — | — | — | — | — | Common Stock | 2,111 | 2,111 | D |
| Stock Option (Right to Buy)F7 | $108.49 | holding | — | — | — | — | Aug 7, 2022 | Common Stock | 12,500 | 12,500 | D |
| Stock Option (Right to Buy)F5 | $108.49 | holding | — | — | — | — | Aug 7, 2022 | Common Stock | 9,375 | 9,375 | D |
| Stock Option (Right to Buy)F8 | $93.32 | holding | — | — | — | — | Jul 31, 2021 | Common Stock | 10,000 | 10,000 | D |
| Stock Option (Right to Buy)F9 | $90.25 | holding | — | — | — | — | Nov 30, 2021 | Common Stock | 5,000 | 5,000 | D |
| Stock Options (Right to buy)F6 | $106.59 | holding | — | — | — | — | Aug 18, 2023 | Common Stock | 13,028 | 13,028 | D |
| Stock Options (Right to buy)F10 | $106.59 | holding | — | — | — | — | Aug 18, 2023 | Common Stock | 17,371 | 17,371 | D |
| Stock Options (Right to buy)F11 | $93.32 | holding | — | — | — | — | Jul 31, 2021 | Common Stock | 16,667 | 16,667 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- F10Vests 4,343 shares on each 8/18/2017, 8/18/2018 and 8/18/2019 and 4,342 shares on 8/18/2020
- F11Fully exercisable
- F2Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F3Vests 3,580 shares on 8/9/2018 and 3,581 shares each on 8/9/2019, 8/9/2020, 8/9/2021.
- F4Each restricted stock unit represents a contingent right to receive one shares of Bio-Techne common stock.
- F5Vests in full or in part on 8/7/18 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F6Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F73,125 shares vest on each of 8/7/16, 8/7/17, 8/7/18 and 8/7/19.
- F82,500 shares vest on each of 7/31/15, 7/31/16, 7/31/17 and 7/31/18.
- F91,500 shares vest on each of 12/1/15, 12/1/16, 12/1/17 and 12/1/18.
Remarks
Due to an administrative error, the Form 4 filed by Reporting Person on February 3, 2017 contained a duplicate of the Table II grants reported in the August 22, 2016 Form 4 filing.